Hugel (145020) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
7 May, 2026Executive summary
Net sales for 4Q24 reached KRW 98.2bn, up 10.4% year-over-year, with full-year sales at KRW 373.0bn, a 16.7% increase year-over-year.
Operating profit for 4Q24 was KRW 46.6bn, up 26.7% year-over-year; full-year operating profit rose 41.2% to KRW 166.3bn.
Net income for 4Q24 surged 130.0% year-over-year to KRW 40.7bn; full-year net income increased 45.8% to KRW 142.4bn.
Financial highlights
Gross profit margin for 4Q24 was 77.2%, up 1.8 percentage points year-over-year.
SG&A expenses decreased 3.4% year-over-year in 4Q24, contributing to improved profitability.
Pre-tax income for 4Q24 was KRW 35.3bn, up 44.4% year-over-year.
Outlook and guidance
Full-year 2024 net sales and operating profit showed strong double-digit growth, indicating positive momentum into the next fiscal year.
Latest events from Hugel
- H1 2024 revenue hit ₩169.7B, net income ₩59.7B, driven by global expansion and strong cash position.145020
Q2 202424 Jun 2026 - Operating profit surged 54.5% year-over-year, driven by strong toxin and global sales growth.145020
Q3 202424 Jun 2026 - Q1 2025 saw double-digit profit growth and global expansion, led by Asia Pacific sales.145020
Q1 202524 Jun 2026 - Double-digit sales growth led by botulinum toxin, derma cosmetics, and surging exports.145020
Q2 202524 Jun 2026 - KRW 305.98bn YTD revenue, lower profit, strong global growth, and robust Derma Cosmetics.145020
Q3 202524 Jun 2026 - Q1 2026 delivered strong growth, led by botulinum toxin and international sales, with robust cash reserves.145020
Q1 202622 Jun 2026 - Global expansion, strong financials, and innovation drive leadership in medical aesthetics.145020
J.P. Morgan HealthCare Conference 2025 presentation7 May 2026 - Targeting global leadership in aesthetics with innovative products and a hybrid U.S. sales model.145020
JP Morgan Healthcare Conference 2026 presentation7 May 2026 - Strong international growth led to a 21.3% YoY sales increase in 4Q25, despite lower net income.145020
Q4 202511 Feb 2026